Highest-materiality recent filing
Z Squared amends Skycore Digital LOI: extends deadline, drops break-up fee, ends exclusivity
Drop dead date extended from June 30, 2026 to January 15, 2027.
Z Squared enters $300M at-the-market equity offering with Roth Capital Partners
Entered Sales Agreement with Roth Capital Partners for at-the-market offering of up to $300M of common stock.
Z Squared appoints Jeffery Harris as CTO; discloses LOI to acquire Paradox Data
Jeffery Harris appointed CTO effective June 24, 2026; annual base salary $225,000 plus RSU bonus of $675,000 and option for 100,000 shares.
Z Squared raises $15.4M equity via SEPA completion, added to Russell 2000/3000
Raised approx $15.3M ($15.4M gross) from sale of 1,302,806 shares at $11.84 to YA II PN under SEPA; no new debt.
Acquisition targets Paradox Data, operator of Union County Campus in El Dorado, AR, with up to 150 MW firm power.
Entered $50M committed equity forward purchase agreement with LucentHash / Data Part Capital; shares issued at 95% of 5-day VWAP.
Z Squared OpCo reports $323K net loss for 2025, no revenue, going concern
Net loss of $323 for year ended Dec 31, 2025 vs $60 in 2024; no revenues generated.
Z Squared Co-CEO Michelle Burke resigns; David Halabu becomes sole CEO
Michelle Burke resigned as Co-CEO and director on May 22, 2026; no disagreement cited.
Phase 1 goal: 100 MW of AI-ready capacity over 18 months across multiple U.S. sites.
Binding LOI to acquire 100% of Skycore Digital; consideration up to $22M in Series B Preferred with 8% dividend.
Coeptis reverse-merger closes; becomes Z Squared crypto miner; ticker now ZSQR
Merger closed April 24, 2026; former Coeptis biopharma assets distributed pre-close as dividend to CHI.
Z Squared completes pro rata distribution of Coeptis Holdings shares and starts trading under ZSQR
Pro rata distribution of Coeptis Holdings, Inc. common stock to shareholders of record on January 2, 2026.
Coeptis completes reverse merger with Z Squared; shares to trade as ZSQR April 27
Coeptis Therapeutics completes business combination with computing infrastructure firm Z Squared Inc.
Nasdaq approves listing of post-merger Coeptis/Z Squared stock under ticker ZSQR
Nasdaq approved listing of post-merger common stock on the Global Market under symbol ZSQR, subject to merger closing.
Coeptis regains Nasdaq listing compliance; officers exchange underwater options for restricted stock
Nasdaq notified Coeptis on Feb 9, 2026 that it regained compliance with annual meeting requirement for continued listing on Nasdaq Capital Market.
Coeptis stockholders approve merger with Z Squared (94% FOR), name change, spinout, new board
3,472,303 shares voted FOR Merger Proposal (94.0% of votes cast); 225,250 AGAINST; merger with Z Squared approved.
Nasdaq letter on Jan 12, 2026 cites violation of Listing Rules 5620(a) and 5810(c)(2)(G) for failing to hold annual meeting within 12 months of fiscal year end (Dec 31, 2024).
Coeptis Therapeutics to merge with Dogecoin miner Z Squared; biopharma spun out
Coeptis to spin out biopharma; Z Squared becomes wholly-owned subsidiary focused on Dogecoin mining.
Coeptis CSO/CMO Colleen Delaney resigns effective March 24; will consult up to 6 months
Colleen Delaney resigned as Chief Scientific and Medical Officer, effective March 24, 2025.
Coeptis raises $1.1M convertible note and completes $10M Series A preferred stock sale
$1.1M convertible note to Yorkville with 8% interest, maturity Dec 31, 2025; conversion price with floor at $1.00.
Coeptis regains Nasdaq bid price compliance; delisting risk resolved
Nasdaq notified Coeptis on Jan 21, 2025 that it regained compliance with Listing Rule 5550(a)(2).
Coeptis Therapeutics proceeds with 1-for-20 reverse stock split; effective after Dec 30
Reverse split ratio set at 1-for-20; effective after market close Dec 30, post-split trading begins Dec 31.
Coeptis shareholders elect 7 directors, approve reverse split and $20M equity issuance
All 7 director nominees elected with ~21M votes each; broker non-votes ~9.9M.
Coeptis launches Tech division, signs LOI for data-security asset buy with 10,000 customers
New division Coeptis Technologies created; binding LOI to acquire Data Placement Manager and Sensitive Content Manager solutions.
Coeptis Therapeutics signs binding LOI to acquire NexGenAI AI marketing platform
Binding letter of intent to acquire NexGenAI Affiliates Network, an AI-powered marketing and RPA platform.
Coeptis Therapeutics enters $20M SEPA with Yorkville, gets $1.3M convertible note
Up to $20M of common stock may be sold to Yorkville at 95% of lowest daily VWAP over 3 days.
Coeptis Therapeutics replaces auditor; prior reports included going concern qualification
Dismissed Turner, Stone & Company as auditor; engaged Astra Audit & Advisory, LLC effective immediately for FY 2024.
Coeptis Therapeutics gets Nasdaq extension to Jan 15, 2025 to regain $1 bid price compliance
Nasdaq Hearings Panel granted continued listing through Jan 15, 2025, subject to compliance with Minimum Bid Price Requirement.
Coeptis says prior financials from Sep 2023 to Mar 2024 not reliable due to accounting errors
Audit committee determined non-reliance on financial statements for Q3 2023, FY 2023, Q1 2024, and related registration statements.
Coeptis receives Nasdaq delisting notice for bid price non-compliance; plans to appeal
Nasdaq notified Coeptis on July 30, 2024 of delisting for failing to maintain $1.00 minimum bid price.
Coeptis raises $4.3M in Series A Preferred financing; CEO granted 2.4M options
Raised $4.3M via sale of 4,300 shares of Series A Preferred at $1,000/share to accredited investors.
Audit committee determined 2022 audited and 2023 quarterly financials are unreliable due to accounting errors.
Coeptis receives Nasdaq deficiency notice for minimum bid price non-compliance
Nasdaq notified Coeptis that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Coeptis stockholders elect 7 directors, approve 5M share equity plan increase
All seven director nominees elected with over 18.98M votes for each, under 24K withheld.
Coeptis Therapeutics posts corporate presentation, no financial details in filing
Company filed an 8-K on Dec 5, 2023, announcing a corporate presentation posted to its website.
Coeptis Therapeutics raises $2M in private placement of stock and warrants
Gross proceeds of $2M from sale of 2M shares (or pre-funded warrants) plus class A and B warrants to healthcare investor.
Coeptis Therapeutics issues 3M shares to two investors for $3M; $500k cash, $2.5M notes due 2024
Issued 2.4M shares to Biofin Ventures for $2.4M ($400k cash + $2M promissory note due Aug 2024).
Coeptis receives Nasdaq deficiency notice for MVLS below $35M minimum
Nasdaq notified Coeptis on Aug 28, 2023 that MVLS has been below $35M for 33 consecutive business days.
Coeptis completes exclusive license of Deverra allogeneic NK cell platform and two Phase 1 assets
Paid ~$570K cash and issued 4M shares to Deverra for exclusive rights to allogeneic stem cell expansion platform.
Coeptis Therapeutics closes $3.5M underwritten offering of common stock and warrants
Offering gross proceeds ~$3.5M before expenses; closed June 16, 2023 to a single healthcare investor.
Coeptis transfers listing from Nasdaq Global Market to Capital Market effective June 13
Received Nasdaq approval on June 8, 2023 to transfer from Global Market to Capital Market.
Coeptis Therapeutics provides investor presentation; no material new data in available excerpt
Company began using an investor presentation deck on June 5, 2023, furnished as Exhibit 99.1.
Coeptis Therapeutics appoints Brian Cogley as CFO; Christine Sheehy steps down
Christine Sheehy steps down as CFO effective May 17, 2023; remains VP of Compliance and Corporate Secretary.
Sponsored research agreement with University of Pittsburgh to advance SNAP-CAR T cells targeting HER2-positive cancers.
Coeptis Therapeutics receives Nasdaq deficiency notice for MVLS below $50M minimum
Nasdaq letter dated Dec. 22, 2022; MVLS below $50M for 30 consecutive business days.
Coeptis Therapeutics completes reverse merger with Bull Horn Holdings; now Nasdaq-listed
Merger closed Oct 28, 2022; Coeptis becomes wholly-owned subsidiary of Bull Horn (renamed Coeptis Therapeutics Holdings).
Bull Horn shareholders approve Coeptis merger; 88.5% of public shares redeemed, trust drops to $3.8M
Shareholders approved all proposals: domestication to Delaware, merger with Coeptis, equity plan, charter amendments, and director election.
Bull Horn Holdings files investor presentation for merger with Coeptis Therapeutics
SPAC Bull Horn Holdings (BHSE) has a Merger Agreement with Coeptis Therapeutics, dated April 18, 2022.
Bull Horn Holdings enters up to $500K working capital note with sponsor
Up to $500,000 promissory note issued to sponsor Bull Horn Holdings Sponsor LLC for working capital; no interest.
Promissory note of up to $400,000 issued to Bull Horn Holdings Sponsor LLC on May 2, 2022.
On June 24, 2026, the Board of Directors (the “Board”) of Z Squared Inc. (the “Company”) appointed Jeffery Harris as Chief Technology Officer of the Company, effective June 24, 2026 (the “Effective Date”).
Following Ms. Burke’s resignation described in Item 5.02(b) above, David Halabu, who had served as a Co-Chief Executive Officer of the Company alongside Ms. Burke since April 24, 2026, will continue to serve as the sole Chief Executive Officer of the Company, effective May 22, 2026.
On May 22, 2026, Michelle Burke notified the Board of Directors (the “Board”) of Z Squared Inc. (the “Company”) of her resignation as Co-Chief Executive Officer and director of the Company, effective May 22, 2026.
On May 22, 2026, Michelle Burke notified the Board of Directors (the “Board”) of Z Squared Inc. (the “Company”) of her resignation as Co-Chief Executive Officer and director of the Company, effective May 22, 2026.
on April 27, 2026, the Board appointed Ryan Schadel to serve as Chief Marketing Officer of the Company.
On April 27, 2026, the Board appointed each of the following individuals to serve in the office set forth opposite his or her name, in each case to hold office at the pleasure of the Board (subject to the terms of any applicable employment or service agreement): • David Halabu — Co-Chief Executive Officer (principal executive officer);
On March 21, 2025, Colleen Delaney submitted her resignation from her role as Chief Scientific and Medical Officer of the Coeptis Therapeutics Holdings, Inc. (the “Company”), effective March 24, 2025.
On May 17, 2023, Coeptis Therapeutics, Inc. (NASDAQ GLOBAL: COEP) (the “Company”) announced that Christine Sheehy is stepping down from her role as Chief Financial Officer of the Company, effective immediately.
On May 17, 2023, the Company announced that Brian Cogley, age 37, was appointed as the Company’s new Chief Financial Officer, effective immediately.
Max materiality 0.95 · Median 0.65 · Most common event other_material